En metaanalyse af 13 kliniske studier med data fra mere end 3800 patienter, som er blevet behandlet med capecitabin, viste i alle studier kombineret at følgende kovarianter var statistisk signifikant associeret med en øget risiko for udviklingen af diarré: stigende capecitabin- startdosis (gram), længere behandlingsvarighed (uger), stigende alder (ved 10- års forøgelse) samt kvindeligt køn.
The results of a meta-analysis of 13 clinical trials with data from over 3800 patients treated with capecitabine showed that in all studies combined, the following covariates were statistically significantly associated with an increased risk of developing diarrhea: increasing capecitabine starting dose (gram), increasing duration of study treatment (weeks), increasing age (by 10 year increments), and female gender.